Medical Director Articles

The term "article" is used to describe any bulletin article, web site article, educational handout or any other non-LCD document intended for public release that contains coverage/coding statements or medical review related billing or claims considerations.

Articles address local coverage, coding or medical review related billing and claims considerations, and may include any newly developed educational materials, coding instructions or clarification of existing medical review related billing or claims policy.

The article listing will continue to expand as additions are made.

Last Updated Jan 30 , 2024
Articles Source Posted
Local Coverage Determinations (LCDs) Finalized - Effective September 22, 2024 Aug 08, 2024
Billing and Coding: MolDX: Afirma™ Assay by Veracyte (A54358) Retirement - Effective July 28, 2024 Aug 01, 2024
Billing and Coding: MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer (A58681) - R6 - Effective August 1, 2024 Aug 01, 2024
Billing and Coding MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing (A58726) - R19 - Effective August 1, 2024 Aug 01, 2024
MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative Neoplasms - Published for Review and Comments Aug 01, 2024
Open Meeting Announcement - MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative Neoplasms - September 13, 2024 Aug 01, 2024
Facet Joint Interventions for Pain Management L38803 - R3 and Billing and Coding: Facet Joint Interventions for Pain Management A58405 - R5 - Effective July 7, 2024 Aug 01, 2024
MolDX: Prostate Cancer Genomic Classifier Assay for Men with Localized Disease (L38341) - R2 - Effective July 25, 2024 Jul 25, 2024
Polysomnography and Other Sleep Studies - Published for Review and Comments Jul 18, 2024
Billing and Coding: MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing (A58720) - R18 - Effective July 1, 2024 Jul 11, 2024
Billing and Coding: MolDX: Repeat Germline Testing (A57332) - R12 - Effective July 1, 2024 Jul 11, 2024
Billing and Coding: MolDX: Minimal Residual Disease Testing for Solid Tumor Cancers (A58454) - R7 - Effective July 11, 2024 Jul 11, 2024
Billing and Coding: MolDX: Molecular Biomarker Testing to Guide Targeted Therapy Selection in Rheumatoid Arthritis (A59522) - R2 - Effective July 1, 2024 Jul 11, 2024
Billing and Coding: Implantable Infusion Pumps for Chronic Pain (A55323) - R17 - Effective July 1, 2024 Jul 05, 2024
Self-Administered Drug Exclusion List (A53033) - R38 - Effective July 1, 2024 Jul 05, 2024
Local Coverage Determinations (LCDs) Finalized - Effective August 18, 2024 Jul 05, 2024
Billing and Coding: MolDX: Proteomics Testing (A59642) - R5 - Effective July 1, 2024 Jul 05, 2024
Billing and Coding: MolDX: Molecular Diagnostic Tests (MDT) (A57527) - R19 - Effective July 1, 2024 Jul 05, 2024
2024 CPT/HCPCS Local Coverage Article (LCA) Updates Jun 27, 2024
MolDX: Pigmented Lesion Assay (L38153) - R1 - Effective June 20, 2024 Jun 20, 2024